✦ LIBER ✦

Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing

✍ Scribed by Cristiana Sessa; Lucia Viganò; Giacomo Grasselli; Josè Trigo; Irene Marimon; Anna Lladò; Alberta Locatelli; Nicoletta Ielmini; Silvia Marsoni; Luca Gianni

Book ID: 116428784
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 450 KB
Volume: 42
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2005.09.033

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I dose-finding and pharmacokinetic

Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors

✍ Noboru Yamamoto; Atsushi Horiike; Yasuhito Fujisaka; Haruyasu Murakami; Tatsu Sh 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 367 KB

1474 POSTER A phase I, open-label study

1474 POSTER A phase I, open-label study with escalating doses of intravenous PTK787/ZK 222584, a multi-VEGF receptor inhibitor, followed by multiple oral daily dosing to assess the absolute bioavailability of PTK787/ZK 222584 after single and multiple doses in advanced cancer patients

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 134 KB

A phase I and pharmacokinetic study of d

A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group

✍ Glenwood Goss; Frances A. Shepherd; Scott Laurie; Isabelle Gauthier; N. Leighl; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 137 KB